
FORM D



UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D. **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

~				
OMB	AP	PR()V A I	

OMB Number: 3235-0076 Expires: April 30, 2008 Estimated average burden hours per response...... 16.00

SEC US	E ONLY
Prefix	Serial
	•
DATE R	ECEIVED
1	1

Name of Offering (check if this is an amendment and name has changed, and indicate change.) Conatus Pharmaccuticals Inc Series A Preferred Stock	1/4 (III A A 111 A A111	
Filing Under (Check box(es) that apply): ☐ Rule 504 ☐ Rule 505 ☒ Rule 506 ☐ Section 4(6) Type of Filing: ☒ New Filing ☐ Amendment	ULOE	
A. BASIC IDENTIFICATION DATA	0806	33742
1. Enter the information requested about the issuer	0000	70772
Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Conatus Pharmaceuticals Inc.		
Address of Executive Offices (Number and Street, City, State, Zip Code) 4365 Executive Drive, Suite 200, San Diego, CA 92121	Telephone Number (Including Area (858) 457-7221	a Code)
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices) Same as above.	Telephone Number (Including Area Same as above.	a Code)
Brief Description of Business Development of innovative human therapeutics to treat liver of	disease.	PROCESSED
Type of Business Organization Solution Ilmited partnership, already formed Ibusiness trust Ilmited partnership, to be formed	other (please specify):	DEC 1 8 2006 THOMSON
Actual or Estimated Date of Incorporation or Organization: Month Year	□ Actual □ Estimated te:	FINANCIAL
CN for Canada; FN for other foreign jurisdiction)	DE	

GENERAL INSTRUCTIONS

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a current valid OMB control number.

1 of 10

A. BASIC IDENTIFICATION DATA Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: Promoter ■ Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Mento, Steven J. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Check Box(es) that Apply: Promoter ■ Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Cashion, Charles J. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Check Box(es) that Apply: Promoter ■ Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Spada, Alfred P. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Check Box(es) that Apply: Promoter ⊠ Beneficial Owner □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Cayer, Jennifer Giottonini Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Check Box(es) that Apply: Promoter ■ Beneficial Owner □ Director ☐ General and/or □ Executive Officer Managing Partner Full Name (Last name first, if individual) **David Hale** Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Check Box(es) that Apply: Promoter Beneficial Owner ☐ Executive Officer ☑ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Paul Klingenstein Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121 Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Patrick Lee Business or Residence Address (Number and Street, City, State, Zip Code) c/o Conatus Pharmaceuticals Inc., 4365 Executive Drive, Suite 200, San Diego, CA 92121

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

	A. BA	ASIC IDENTIFICATION	N DATA		
 Enter the information requested for the Each promoter of the issuer, if the Each beneficial owner having the Each executive officer and directed Each general and managing parts 	ne issuer has been organized e power to vote or dispose, tor of corporate issuers and	or direct the vote or dispo	sition of, 10% o	or more of a class of equity securities of the issuer; ers of partnership issuers; and	
Check Box(es) that Apply: Promoter	⊠ Beneficial Owner	Executive Officer	□ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual) William Gerber					
Business or Residence Address (Number c/o Conatus Pharmaceuticals Inc., 4365	•				
Check Box(es) that Apply: Promoter	☐ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Aberdare Ventures III, L.P.					
Business or Residence Address (Number One Embarcadero Center, Suite 4000, S		Code)			
Check Box(es) that Apply: Promoter	⊠ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Bay City Capital Fund IV, L.P.					
Business or Residence Address (Number 750 Battery Street, Suite 400, San Franc		Code)			
Check Box(es) that Apply:	■ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Advent Private Equity Fund IV					
Business or Residence Address (Number 25 Buckingham Gate, London, United K		Code)			
Check Box(es) that Apply: Promoter	☑ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner	
Full Name (Last name first, if individual) Steven J. Mento and Linda A. Mento as	Trustees under the Mento	o Family Trust Dated De	cember 29, 199	4	
Business or Residence Address (Number 16036 Country Day Road, Poway, CA 92	•	Code)			
Check Box(es) that Apply: Promoter	■ Beneficial Owner	☐ Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if individual) Charles J. Cashion and Martha Diane Coor any Successor Trustee thereunder	ashion, as Trustee UDT D	Dated July 27, 1988, when	rein Charles J.	Cashion and Martha Diane Cashion are Trustor	s,
Business or Residence Address (Number 18778 Olmeda Place, San Diego, CA 921		Code)	· ·		
Check Box(es) that Apply: Promoter	⊠ Beneficial Owner	Executive Officer	Director	General and/or Managing Partner	
Full Name (Last name first, if individual) The Paul E. Cayer and Jennifer G. Caye	r Trust Dated March 1, 2	005			
Business or Residence Address (Number 14112 Bahama Cove, Del Mar, CA 92014		Code)	, -		
 	(Use blank sheet, or copy	and use additional copies	of this sheet, as	necessary.)	

A. BASIC IDENTIFICATION DATA Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Check Box(es) that Apply: Promoter ■ Beneficial Owner ■ Executive Officer □ Director ☐ General and/or **Managing Partner** Full Name (Last name first, if individual) Hale BioPharma Ventures LLC Business or Residence Address (Number and Street, City, State, Zip Code) 1042-B N. El Camino Real, Suite 430, Encinitas, CA 92024-1322 ☐ Executive Officer ☐ Director Check Box(es) that Apply: Promoter Beneficial Owner ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Beneficial Owner ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Beneficial Owner ■ Executive Officer ☐ General and/or □ Director Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) ☐ Beneficial Owner ■ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: Promoter ■ Beneficial Owner □ Executive Officer □ Director General and/or **Managing Partner** Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) ☐ Beneficial Owner ☐ Executive Officer □ Director ☐ General and/or

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Managing Partner

				·	B. INFORM	ATION ABO	OUT OFFER	RING				
					_							No
1. Has	the issuer sol	d, or does the i										\boxtimes
2. Wha	ıt is the minin	ıum investmer			appendix, Colom any indivi						\$0.75	
											Yes	No
3. Doe	s the offering	permit joint o	wnership of a	single unit?		•••••					፟ .	
remo pers than	uneration for on or agent of	solicitation of La broker or d	purchasers ir ealer register	n connection ed with the S	with sales of SEC and/or w	securities in ith a state or	the offering. states, list th	If a person t e name of the	o be listed is e broker or d	sion or similar an associated ealer. If more that broker or		
	ne (Last nam ot applicable	e first, if indiv	idual)									
Busines	s or Residenc	e Address (Nu	mber and Str	eet, City, Sta	te, Zip Code)						
Name of	f Associated I	Broker or Deal	ег									
		n Listed Has S										
(Check	"All States": ☐ AK	or check indiv □ AZ	idual States) ☐ AR	□ CA	co	СТ	☐ DE	□ DC	☐ FL	□GA	□ні	☐ All States ☐ ID
	□ in	□IA	□ KS	□ KY	☐ LA	□ ме	Ш́мD	🗌 МА	□ мі	☐ MN	☐ MS	Дмо
☐ MT	□ NE □ SC	□ NV	□ NH □TN	□ tx	□ NM □ UT	□ NY □ VT	□ NC □ VA	□ ND □ WA	□ oh □ wv	□ ok □ wi	☐ OR ☐ WY	□ PA □ PR
E. II Mas		Gar Chalin	idual)									
ruii Nai	ne (Last nam	e first, if indivi	iduai)									
Busines	s or Residence	e Address (Nu	mber and Str	eet, City, Sta	ite, Zip Code))						<u> </u>
Name of	f Associated I	Broker or Deal	er									
		n Listed Has S										
(Check	"All States"	or check indiv	idual States)	П С 4	[] (O	Пст	□ DF	DC	☐ FL			☐ All States ☐ ID
□ IL	☐ IN	∐ IA	∐ KS	∐ KY	L⊿ LA	∐ ME	∐ MD	⊔ MA	☐ MI	☐ MN	\square MS	□ мо
☐ MT ☐ RI	☐ NE ☐ SC	□ NV □ SD	□ NH □ TN	□ IVJ □ TX	□ NM □ UT	□ NY □ VT	□ NC □ VA	□ ND □ WA	□ oн □ wv	□ ok □ wi	□ OR □ WY	□ PA □ PR
Full Nar	ne (Last name	e first, if indivi	idual)									
D		. A 1 June (A)	l1 C4	or Circ Cr	7(n, C-4n)							
Busines	s or Residence	e Address (Nu	mber and Sin	eet, City, Sta	te, Zip Code)	1						
Name of	f Associated I	Broker or Deal	er					-				
		n Listed Has S			icit Purchasei	rs					<u>.</u>	
(Check	"All States": ☐ AK	or check indiv AZ	idual States) ☐ AR	□ CA	□ co	□ст	☐ DE	□ DC	☐ FL	□GA	□ні	☐ All States ☐ ID
□IL	□IN	□ IA	□ κs	□ KΥ	☐ LA	☐ ME	☐ MD	☐ MA	□ мі □ он	☐ MN ☐ OK	☐ MS	□ MO □ PA
∏ МТ ∏ RI	□ NE □ SC	□ NV □ SD	□ NH □ TN	□ ил □ тх	□ NM □ UT	□ NY □ VT	□ NC □ VA	□ ND □ WA	□ wv	□ wi	□ WY	

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\) and indicate in the columns		
	below the amounts of the securities offered for exchange and already exchanged. Type of Security	Aggregate Offering Price	Amount Already Sold
	Debt	\$0,00	\$0.00
	Equity	\$27,370,662.00	\$6,620,663.25
	☐ Common ☑ Preferred <u>Series A</u>	<u>\$0.00</u>	\$0.00
	Convertible Securities (including warrants)	\$0.00	\$0.00_
	Partnership Interests	\$0.00	\$0.00
	Other (Specify)	\$0.00	\$0.00
	Total		\$6,620,663,25
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
		Number Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	_22_	\$6,620,663.25
	Non-accredited Investors	<u> </u>	\$0.00
	Total (for filings under Rule 504 only)		
	Answer also in Appendix, Column 4, if filing under ULOE.		
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.		
	Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		
	Regulation A		
	Rule 504		
	Total		
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		<u>\$0.00</u>
	Printing and Engraving Costs		<u>\$0.00</u>
	Legal Fees	🗵	\$121,000.00
	Accounting Fees		<u>\$0.00</u>
	Engineering Fees		\$0.00
	Sales Commissions (specify finders' fees separately)		\$0.00
	Other Expenses (identify)		\$0.00
	Total		\$121,000.00

5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Part C - Question 4.b above. Payments to Officers, Directors, & Affiliates Ofters Salaries and fees	total expenses formished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer". 5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4 b above. Payments to Officers, Affiliates Salaries and fees. Purchase of real estate Purchase of real estate Purchase, rental or leasing and installation of machinery and equipment. Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer prusuant to a merger). Repayment of indebtedness Working capital. Other (specify): D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filled under Rule 505, the following signature constitute an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer any non-accredited investor pursuant to a mergaph (b)(2) of Rule 502. Suscer (Print or Type) Date: Date Dat		C. OFFERING PRICE, NUMBER	R OF INVESTORS, EXPENSES AND USE C	OF PRO	CEED	<u>s</u>	<u> </u>	•
purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above. Payments to Officers, & Affiliates Payments to Officers, & Affiliates Payments to Officers, & Affiliates Others	purposes shown. If the amount for any purposes is not known, famish an estimate and check the box to the left of the estimate. The total of the apyments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4 b above. Payments to Officers,		total expenses furnished in response to Part C - Question 4.a. The	This difference is the "adjusted gross proceeds				<u>\$27,2</u> 4	49 <u>,662.00</u>
Payments to Officers, Directors, & Payments Officers, Directors, & Officers, Directors, & Affiliates Salaries and fees	Payments to Officers, Directors, & Payments to Officers, Directors, & Payments to Officers, Directors, & Affiliates Salaries and fees	5.	purposes shown. If the amount for any purpose is not known, furnish estimate. The total of the payments listed must equal the adjusted gro	sh an estimate and check the box to the left of the					
Salaries and fees	Salaries and fees. \$0.00 \$0.00 Purchase of real estate \$0.00 \$0.00 Purchase of real estate \$0.00 \$0.00 Purchase, rental or leasing and installation of machinery and equipment \$0.00 \$0.00 Construction or leasing of plant buildings and facilities \$0.00 \$0.00 Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$0.00 \$0.00 Repayment of indebtedness \$0.00 \$0.00 Working capital \$0.00 \$27,249,662.00 Other (specify): \$0.00 \$0.00 Column Totals \$0.00 \$27,249,662.00 D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitute an undertaking by the issuer to farmish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accreticated investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signatur Date 11/20/06 Name of Signer (Print or Type) Title of Signer (Print or Type)		Tate - Quarton 1.0 more.			Offic Directo	eers, ors, &		
Purchase, rental or leasing and installation of machinery and equipment	Purchase, rental or leasing and installation of machinery and equipment		Salaries and fees	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	□ \$ 0		_	_	
Construction or leasing of plant buildings and facilities	Construction or leasing of plant buildings and facilities. \$0.00 \$0.00 Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$0.00 \$0.00 Repayment of indebtedness \$0.00 \$0.00 Working capital \$0.00 \$27,249,662.00 Other (specify): \$0.00 \$27,249,662.00 Column Totals \$0.00 \$27,249,662.00 Total Payments Listed (column totals added) \$27,249,662.00 D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitute an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff. the information furnished by the issuer tany non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signatural Date 11/20/06 11/20		Purchase of real estate	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	□ <u>\$0</u>).00 <u></u>	С] <u>\$0.00</u>	
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$0.00 \$0.	Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$0.00		Purchase, rental or leasing and installation of machinery and	equipment	□ <u>\$0</u>).00	Е] <u>\$0.00</u>	_
offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)	offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) \$0.00 \$		Construction or leasing of plant buildings and facilities		□ <u>\$0</u>	0.00	E	\$0.00	-
issuer pursuant to a merger) \$0.00 \$0.00 Repayment of indebtedness \$0.00 \$0.00 Working capital \$0.00 \$27,249.662 Other (specify): \$0.00 \$27,249.662 Total Payments Listed (column totals added). \$27,249.662 Total Payments Listed (column totals added). \$27,249.662 D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constituent undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signatur Conatus Pharmaceuticals Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)	issuer pursuant to a merger) \$0.00 \$0.00 \$0.00 Repayment of indebtedness \$0.00 \$0.00 Working capital		Acquisition of other business (including the value of securiti	ies involved in this					
Repayment of indebtedness	Repayment of indebtedness \$0.00 \$0.00 Working capital \$0.00 \$27,249,662.00 Other (specify): Solution Totals \$0.00 \$27,249,662.00 Column Totals Listed (column totals added). D. FEDERAL SIGNATURE The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitute an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Signatur Conatus Pharmaceuticals Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)		offering that may be used in exchange for the assets or securi issuer pursuant to a merger)	ities of another	□ <u>\$0</u>	0.00] <u>\$0.00</u>	
Working capital	Working capital		- ·		□ <u>\$0</u>). <u>00</u>	С] <u>\$0.00</u>	=
Column Totals	Column Totals		Working capital		□ <u>\$0</u>	00.0	Þ	\$27,2	49,662.00
Total Payments Listed (column totals added)	Column Totals		Other (specify):						
Total Payments Listed (column totals added)	Column Totals				П <i>а</i> с		г	7	
Total Payments Listed (column totals added)	Total Payments Listed (column totals added)				ليا يين).00 °	_	1 <u>\$0.00</u>	•
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitution and undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issue any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Date 11/20/06 Title of Signer (Print or Type)	The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitute an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Date 1 20 06 Title of Signer (Print or Type)		Column Totals		□ <u>\$0</u>).00	Ø	\$27,24	<u>49,662.00</u>
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitution and undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuent any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)	The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitute an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Title of Signer (Print or Type) Title of Signer (Print or Type)		Total Payments Listed (column totals added)				⊠ \$27,24	9,662.00	
an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issue any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Date 11 20 06 Title of Signer (Print or Type)	an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502. Issuer (Print or Type) Conatus Pharmaceuticals Inc. Date 1 20 06 Title of Signer (Print or Type)	Г	r	D. FEDERAL SIGNATURE					
Conatus Pharmaceuticals Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)	Constus Pharmaceuticals Inc. Name of Signer (Print or Type) Title of Signer (Print or Type)	an	undertaking by the issuer to furnish to the U.S. Securities and Ex-	xchange Commission, upon written request of i					
				has I know	_	1		106	
Charles J. Cashion Senior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer	Charles J. Cashion Scnior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer		,,,,,	· · · · · · · · · · · · · · · · · · ·)		1	f	
		Ch	arles J. Cashion Senior	Vice President, Finance, Chief Financial Office	cer, Sec	retary a	and Treasurer		
			·	· community of the					
				- ATTENTION					
ATTENTION		I	Intentional misstatements or omissions of fact const	titute federal criminal violations. (S	See 18	U.S.C	C. 1001.)		

	man de	E. STATE SIGNATURE
1.		262 presently subject to any of the disqualification provisions Yes No
		See Appendix, Column 5, for state response.
2.	The undersigned issuer hereby underta at such times as required by state law.	akes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239.500)
3.	The undersigned issuer hereby underta	ikes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.
4.		at the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform Limited Offering hich this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of been satisfied. N/A
he iss erson.		s the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized
ssucr (Print or Type)	Signature Date
Constu	is Pharmaceuticals Inc.	11/20/06
Name (Print or Type)	Title (Print or Type)
Charle.	s J. Cashion	Senior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer

Instruction:
Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

				A	PPENDIX				
l		2	3		<u> </u>	4			5
	non-acc	to sell to credited s in State Item 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)		amount purc	nvestor and chased in State C-Item 2)		under ULOE atta explana waiver	lification r State (if yes, ach ation of granted) -Item 1)
			Aggregate Amount of Series A Preferred	Number of Accredited		Number of Non- Accredited			
State AL	Yes	No	Stock to be sold	Investors	Amount	Investors	Amount	Yes	No
AK									
									ļ
AZ									<u> </u>
AR									
CA		×	\$19,870,662.00	13	\$5,120,663.25	0	\$0.00		×
со				. <u>.</u>					
СТ		i							
DE									
DC									
FL		:							
GA									
ні									
ID									
IL		:							
IN									
1A									
KS									
KY								· -	
LA									
ME	-			· ···· · · · · · · · · · · · · · · · ·					
MD									
MA									
MI									
MN									
MS									
МО									
1				į					L

APPENDIX 1 2 3 5 Disqualification under State Intend to sell to ULOE(if yes, non-accredited Type of security and attach Type of investor and investors in aggregate offering explanation of amount purchased in State price offered in state State waiver granted) (Part C-Item 2) (Part C-Item 1) (Part E-Item 1) (Part B Item 1) Number of Aggregate Amount of Number of Non-Series A Preferred Accredited Accredited State Yes No Stock to be sold Investors Amount Investors Yes No Amount MT NE NV NH NJ NM NY NC ND ОН OK OR PA RI SC SDTNTXŲΤ VTVA WA WV WΙ WY PR